Stephen Curtis

Stephen Curtis has a diverse work experience in the biopharmaceutical and venture capital industry. Stephen is currently working as the Director of New Ventures at BrightEdge, where they invest in early-stage companies developing cancer-focused therapeutics and technologies. Prior to this, Stephen worked at NextPoint Therapeutics as a Strategy/Business Development Consultant and later as the Interim COO/Board of Directors, leading strategic initiatives and business development efforts. Stephen also has experience at MPM Capital as a Founding Board Member and COO/CBO of Stealth NewCos, and as a Managing Director of Oncology Innovations, where they managed the investment collaboration with Dana-Farber Cancer Institute. Before that, they worked at Eli Lilly and Company as the Senior Director of Business Development for Emerging Technology and Innovation. Stephen also has experience at 2M Companies, Reata Pharmaceuticals, Siemens Venture Capital, and the Laboratory of Dr. Carla Kim at Harvard Medical School, where they conducted research on lung cancer. Additionally, they served as a Co-Chair of the Boston Chapter and the Healthcare SIG at Kauffman Fellows and completed the Kauffman Fellows Program as a Fellow in Class 20.

Stephen Curtis earned their Bachelor of Science (B.S.) degree in Molecular and Cellular Biology as well as Applied Economics and Management from Cornell University, where they studied from 2001 to 2006. Stephen then pursued their Doctor of Philosophy (Ph.D.) degree in Biological and Biomedical Sciences from Harvard Medical School, graduating in 2011.